Innate Pharma to present at AACR partnering event
Innate Pharma S.A., a clinical-stage immuno-oncology company listed on Euronext Paris and Nasdaq, announced that Chief Operating Officer Yannis Morel will present at the AACR Oncology Industry Partnering Event in San Diego.
Rhea-AI Filing Summary
Innate Pharma S.A., a clinical-stage immuno-oncology company listed on Euronext Paris and Nasdaq, announced that Chief Operating Officer Yannis Morel will present at the AACR Oncology Industry Partnering Event in San Diego. The April 16, 2026 showcase session will allow Innate to highlight its oncology pipeline, including key assets such as IPH4502, a Nectin4 antibody-drug conjugate for solid tumors, lacutamab for cutaneous and peripheral T cell lymphomas, and monalizumab, developed with AstraZeneca, for non-small cell lung cancer. The company views this invitation as recognition of its clinical pipeline and an opportunity to engage directly with investors and industry partners.
Positive
- None.
Negative
- None.
Key Figures
Presentation date: April 16, 2026
Presentation time: 6:10 PM PDT
Report date: April 8, 2026
+1 more
4 metrics
Presentation date
April 16, 2026
AACR Oncology Industry Partnering Event showcase session
Presentation time
6:10 PM PDT
Showcase Session 2 at San Diego Convention Center
Report date
April 8, 2026
Date of Form 6-K report and press release
Financial year referenced
Year ended December 31, 2025
Referenced in relation to Innate Pharma’s Annual Report on Form 20-F
Key Terms
Nectin4 ADC, cutaneous T cell lymphomas, non-small cell lung cancer, Universal Registration Document, +1 more
5 terms
Nectin4 ADC medical
"including IPH4502, a differentiated Nectin4 ADC developed in solid tumors"
cutaneous T cell lymphomas medical
"lacutamab, an anti-KIR3DL2 antibody developed in cutaneous T cell lymphomas"
non-small cell lung cancer medical
"monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer (NSCLC)"
A broad category of lung tumors that grow from the cells lining the airways and make up the majority of lung cancer cases; it includes several subtypes that behave and respond to treatment differently, like different models of the same car family. It matters to investors because its large patient population and variety of treatment options — surgery, traditional chemo, targeted drugs and immunotherapies — create major markets where clinical trial results, drug approvals or changing treatment guidelines can quickly affect a company’s revenue and stock value.
Universal Registration Document regulatory
"Risk Factors section of the Universal Registration Document filed with the French Financial Markets Authority"
A universal registration document is a single, comprehensive filing that collects a publicly traded company's key disclosures — such as business description, financial statements, risk factors, governance and legal information — into one place for regulators and investors. Think of it as a detailed owner’s manual and scorecard combined: it saves time when the company issues new shares or bonds and helps investors compare, check risks, and make informed decisions without hunting through many separate reports.
immunotherapies medical
"a global, clinical-stage biotechnology company developing immunotherapies for cancer patients"
Immunotherapies are medical treatments that strengthen or guide the body's own immune system to recognize and fight disease cells, such as cancer or chronic infections. They matter to investors because they can produce long-lasting patient responses, command premium prices, and reshape standard care—similar to installing a smarter security system that prevents repeat break-ins—creating significant commercial upside but also clinical and regulatory risk.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Innate Pharma (IPHA) announce in its latest Form 6-K?
Innate Pharma announced that its COO, Yannis Morel, will present at the AACR Oncology Industry Partnering Event. The showcase session highlights Innate’s oncology pipeline, including IPH4502, lacutamab, and monalizumab, to an audience of investors and industry leaders focused on cancer drug development.
When and where will Innate Pharma present at the AACR Oncology Industry Partnering Event?
Innate Pharma will present on Thursday, April 16, 2026, at 6:10 PM PDT at the San Diego Convention Center. The presentation is part of Showcase Session 2 of the AACR Oncology Industry Partnering Event: From Cancer Discoveries to Patients.
Which pipeline assets will Innate Pharma (IPHA) highlight at the AACR partnering event?
Innate Pharma plans to highlight its key oncology assets, including IPH4502, a differentiated Nectin4 antibody-drug conjugate for solid tumors, lacutamab for cutaneous and peripheral T cell lymphomas, and monalizumab, an anti-NKG2A antibody developed with AstraZeneca for non-small cell lung cancer.
What is the AACR Oncology Industry Partnering Event and why is it important for Innate Pharma?
The AACR Oncology Industry Partnering Event is an annual forum connecting venture capitalists, bankers, and biotech and pharma leaders. It offers Innate Pharma direct exposure to analysts and investors, providing a platform to showcase its oncology pipeline, strategy, and clinical progress in immuno-oncology.
How does Innate Pharma describe its business focus in this 6-K filing?
Innate Pharma describes itself as a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. It emphasizes expertise in antibody engineering, innovative target identification, and a portfolio of potential first- or best-in-class antibody therapeutics addressing areas of high unmet medical need.
Which major partners collaborate with Innate Pharma (IPHA) on its oncology programs?
Innate Pharma notes collaborations with leading biopharmaceutical companies Sanofi and AstraZeneca, as well as academic and research institutions. These partnerships support the advancement of its immuno-oncology pipeline, including co-development of monalizumab with AstraZeneca for non-small cell lung cancer indications.
AI-generated analysis. How Rhea-AI works. Not financial advice.
